Trials / Completed
CompletedNCT01187836
Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure
A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patients With Stable Heart Failure
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Trevena Inc. · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
In this study, TRV120027 (or a placebo) intravenous infusion will be given to people with heart failure to learn about the effects of TRV120027. The results of this study will help choose the proper range of TRV120027 doses to use in future research studies involving patients with acute decompensated heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRV120027 | Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours. |
| DRUG | Placebo | Placebo administered for 14 hours. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2012-03-01
- Completion
- 2012-03-01
- First posted
- 2010-08-24
- Last updated
- 2017-07-11
Locations
9 sites across 3 countries: United States, Czechia, Poland
Source: ClinicalTrials.gov record NCT01187836. Inclusion in this directory is not an endorsement.